News >

Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers

Shannon Connelly
Published: Thursday, May 03, 2018

John L. Marshall, MD

John L. Marshall, MD
Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

“This is a little bit of a gold rush,” said Marshall, professor of medicine and oncology, director of the Otto Reusch Center for the Cure of GI Cancer, Medstar Georgetown University Medical Center. “Our patients very much want to try one of these immunotherapy drugs, and in all of our patients with metastatic disease, we want to try one—because when they work, they work big.”
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual International Congress on Oncology & Pathology™Aug 30, 20201.5
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Publication Bottom Border
Border Publication
x